Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat

Research output: Contribution to journalJournal articleResearchpeer-review

  1. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas

    Research output: Contribution to journalReviewResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Letter to the editor regarding proposed new diagnostic criteria for migraine

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) are potent vasodilators in animals and humans. PACAP infusion but not VIP infusion precipitates migraine attacks in migraine patients. The vascular effects of VIP and the two varieties of PACAP (PACAP-27 and PACAP-38) were investigated versus selective antagonists in segments of rat middle cerebral arteries (MCA), basilar arteries (BA) and middle meningeal arteries (MMA) using myographs. The luminal and abluminal effects of VIP were studied using perfusion myograph. mRNA expression of the relevant receptors (VPAC(1), VPAC(2) and PAC(1)) was examined by in situ hybridization. There was no significant difference in relaxant potency of the peptides in the MCA. In BA the relaxant potency was VIP>PACAP-27=PACAP-38. Relaxant responses were either absent or very weak in MMA. VIP was found to be somewhat more potent in BA than in the MCA. Maxadilan, a selective PAC(1)-receptor agonist, showed no relaxant effect in either vessel. The VPAC(2)-antagonist PG 99-465 alone proved ineffective in the MCA, while it had a weak effect on BA. The VPAC(1)-antagonist PG 97-269 inhibited relaxation induced by both VIP and the PACAPs in cerebral vessels. In combination, the two antagonists demonstrated better effect than either alone. VIP applied luminally via perfusion myograph caused no dilatation, indicating lack of endothelial involvement. In situ hybridization demonstrated the presence of mRNA for all three receptors in the smooth muscle cells of the vessels. In conclusion, migraine-like headache induced by PACAP-38 infusion is unlikely to be caused by direct vasodilator action on intracranial vessels.
Original languageEnglish
JournalEuropean Journal of Pharmacology
Volume670
Issue number1
Pages (from-to)186-94
Number of pages9
ISSN0014-2999
DOIs
Publication statusPublished - 2011

    Research areas

  • Angiography, Animals, Arteries, Gene Expression Regulation, Humans, Ligands, Male, Myography, Pituitary Adenylate Cyclase-Activating Polypeptide, Pressure, RNA, Messenger, Rats, Rats, Sprague-Dawley, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Receptors, Vasoactive Intestinal Peptide, Vasoactive Intestinal Peptide

ID: 34616172